Literature DB >> 21710249

Cyclophosphamide followed by mizoribine as maintenance therapy against refractory steroid-dependent nephrotic syndrome.

Shuichi Ito, Hirokazu Ikeda, Tomonori Harada, Koichi Kamei, Eihiko Takahashi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21710249     DOI： 10.1007/s00467-011-1948-0

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  10 in total

1.  Eight and 12 week courses of cyclophosphamide in nephrotic syndrome.

Authors:  N Ueda; K Kuno; S Ito
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

2.  Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration.

Authors:  Shuichiro Fujinaga; Daishi Hirano; Naoto Nishizaki; Tomonosuke Someya; Yoshiyuki Ohtomo; Yoshikazu Ohtsuka; Toshiaki Shimizu; Kazunari Kaneko
Journal:  Pediatr Nephrol       Date:  2010-12-21       Impact factor: 3.714

3.  Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome.

Authors:  M J Kemper; H Altrogge; K Ludwig; K Timmermann; D E Müller-Wiefel
Journal:  Pediatr Nephrol       Date:  2000-08       Impact factor: 3.714

4.  Cyclophosphamide in steroid-dependent nephrotic syndrome.

Authors:  Sonia Azib; Marie Alice Macher; Theresa Kwon; Agnes Dechartres; Corinne Alberti; Chantal Loirat; Georges Deschênes; Véronique Baudouin
Journal:  Pediatr Nephrol       Date:  2011-03-12       Impact factor: 3.714

5.  Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome.

Authors:  Alberto Zagury; Anne Louise de Oliveira; Carlos Augusto Pinheiro de Moraes; Jose Augusto de Araujo Montalvão; Regina Helena Leite Lemos Novaes; Vinicius Martins de Sá; Deise De Boni Monteiro de Carvalho; Tereza Matuck
Journal:  Pediatr Nephrol       Date:  2011-03-13       Impact factor: 3.714

6.  Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.

Authors:  Eiske M Dorresteijn; Joana E Kist-van Holthe; Elena N Levtchenko; Jeroen Nauta; Wim C J Hop; Albert J van der Heijden
Journal:  Pediatr Nephrol       Date:  2008-07-12       Impact factor: 3.714

7.  Management of childhood onset nephrotic syndrome.

Authors:  Debbie S Gipson; Susan F Massengill; Lynne Yao; Shashi Nagaraj; William E Smoyer; John D Mahan; Delbert Wigfall; Paul Miles; Leslie Powell; Jen-Jar Lin; Howard Trachtman; Larry A Greenbaum
Journal:  Pediatrics       Date:  2009-07-27       Impact factor: 7.124

8.  Management patterns of childhood-onset nephrotic syndrome.

Authors:  Nathaniel MacHardy; Paul V Miles; Susan F Massengill; William E Smoyer; John D Mahan; Larry Greenbaum; Sara Massie; Lynne Yao; Shashi Nagaraj; Jen-Jar Lin; Delbert Wigfall; Howard Trachtman; Yichun Hu; Debbie S Gipson
Journal:  Pediatr Nephrol       Date:  2009-08-12       Impact factor: 3.714

9.  Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome.

Authors:  Kamran Afzal; Arvind Bagga; Shina Menon; Pankaj Hari; Stanley C Jordan
Journal:  Pediatr Nephrol       Date:  2007-10-16       Impact factor: 3.714

Review 10.  Non-corticosteroid treatment for nephrotic syndrome in children.

Authors:  E M Hodson; N S Willis; J C Craig
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
  10 in total
  1 in total

1.  Uncertainty in management of childhood-onset idiopathic nephrotic syndrome: is the long-term prognosis really favorable?

Authors:  Shuichiro Fujinaga; Amane Endo; Yoshiyuki Ohtomo; Yoshikazu Ohtsuka; Toshiaki Shimizu
Journal:  Pediatr Nephrol       Date:  2013-07-09       Impact factor: 3.714
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.